T he prognosis of pancreatic carcinoma has not improved in the past 20 years. Despite the recent advances in diagnostic techniques, it remains difficult to diagnose this devastating disease in the early stage. Developing informative noninvasive cancer biomarkers is essential to achieve early detection of tumors to better stratify patients' prognosis and to optimize therapy for individual patients with cancer. Unique to pancreatic adenocarcinoma is the high incidence of Kirsten rat sarcoma (K-ras) mutations reported (approximately 95%). Patients with pancreatic ductal adenocarcinoma shed cells that harbor K-ras mutations and circulate in the peripheral blood. We recently established a real-time polymerase chain reaction (PCR) assay with mutant-specific hybridization probes combined with peptide nucleic acid (PNA)-mediated PCR clamping of the wild-type alleles to identify K-ras codon 12-point mutations in plasma samples of patients with pancreatic cancer and acute myeloid leukemia. We demonstrated that this reliable and fast method allows quantitative detection of altered alleles with a very high sensitivity (1:100,000, mutated to wild-type alleles) and might provide diagnostic and prognostic information to physicians, especially when combined with determination of serum cancer-associated antigen 19-9 (CA 19-9). Here, we extend our previous findings by showing that K-ras mutations in the plasma correspond to computed tomographic (CT) findings in patients with pancreatic cancer and provide further evidence that K-ras mutation analysis in plasma is useful for detection and prognostic evaluation of pancreatic carcinoma.
RESULTS AND DISCUSSION
The diagnosis of pancreatic cancer is typically made radiographically, and contrast-enhanced CT scanning is the preferred method to diagnose and stage pancreatic cancer. In addition, several serum markers for pancreatic cancer have been evaluated, the most useful of which is CA 19-9. Owing to limited sensitivity and specificity, CA 19-9 is not recommended as a screening test for pancreatic cancer. However, serial monitoring of CA 19-9 levels is useful to follow patients after potentially curative surgery and for those who are receiving chemotherapy for advanced disease. Therefore, rising CA 19-9 levels usually precede the radiographic appearance of recurrent disease, but confirmation of disease progression should be pursued with imaging studies and/or biopsy. In this regard, the addition of molecular genetic analysis may improve sensitivity and may be helpful in the diagnostic evaluation for pancreatic masses at initial presentation and in particular during the clinical follow-up setting.
Pancreatic cancer is unique in its high frequency of K-ras mutations. Because of the inherent difficulties in obtaining pancreatic tumor tissue for molecular analysis, detection of K-ras mutations in the plasma DNA might provide physicians with prognostic information of a patient with pancreatic cancer. It has been established that 80% of tumors shed cell-free DNA into blood 1 and that the correspondence of K-ras mutations in the pancreatic cancer tissue and circulating plasma DNA is almost equal. 2 Previous studies have also reported that 35% to 81% of K-ras mutations were detected in plasma of patients with pancreatic cancer 3 and showed that the sensitivity was from 27% to 81%. 2 In addition, it has been shown that K-ras mutation in plasma DNA is a predictive biomarker for a poor prognosis of patients with pancreatic cancer. 2, 4 Therefore, the disposition of blood-borne tumor mutations, detectable in plasma, may provide additional insight into a patient's response to therapy and could potentially be used as an early indicator of tumor recurrence.
In fact, our previously published data indicate that the occurrence or absence of K-ras mutations in the peripheral blood of patients with pancreatic cancer might reflect different tumor stages in a patient, depending on the time of observation, indicating that the detection of K-ras mutations in plasma could reflect the tumor burden of individual patients with pancreatic cancer. 5 To evaluate the use of plasma K-ras analysis as a marker for the course of disease, we correlated the presence of mutated K-ras in the plasma of patients with pancreatic cancer with CT findings and the conventional tumor marker CA 19-9. Thirty-eight patients with pancreatic cancer were enrolled in the study. Patients' characteristics are summarized in Table 1 . We prospectively collected 86 serum samples for determination of CA 19-9 levels and 86 plasma samples for analysis of K-ras mutations of these patients as described previously 5Y7 at the time when contrast-enhanced CT with thin (1 mm) sections of the abdomen was performed during the clinical follow-up after initial presentation.
Plasma K-ras mutations were identified in 15 (39%) of 38 patients with pancreatic cancer, which is in agreement with previous studies. 3, 8 Elevated CA 19-9 levels were found in 29 (76%) of the 38 patients using a cutoff value higher than 37 IU/mL. Levels of CA 19-9 were elevated in 62 serum samples (72%), in which the K-ras assay in corresponding plasma samples showed a mutation in 13 cases (21%). Furthermore, in 3 (13%) of 24 plasma samples with corresponding CA 19-9 levels lower than 37 IU/mL, the T1  1  T2  5  T3  12  T4 20 CA 19-9, IU/mL G37 9
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Computed tomographic findings of complete remission, partial remission, and stable disease were associated with plasma K-ras wild type in 91% (10/11), 80% (4/5), and 89% (17/19) of the cases, respectively. CA 19-9 serum levels were elevated in 50% (7/14) serum samples, whereas corresponding CT scans showed disease remission and plasma samples showed no K-ras mutation. Otherwise, CA 19-9 serum levels were normal in all patients with detectable K-ras mutation, whereas the corresponding CT scan showed disease remission. Computed tomographic findings of disease progress were associated with plasma K-ras mutations in 24% (12/51) of the cases. Of the remaining 39 plasma samples with K-ras wild-type verification, despite signs of disease progress in CT, 32 (82%) corresponding serum samples showed elevated CA 19-9 levels. Detectable K-ras mutations in the plasma were clearly associated with corresponding CT scans with signs of progressive disease in 75% (12/16), whereas at the time of verification of plasma K-ras wild type, 44% (31/70) of corresponding CT scans showed no signs of disease progression or stable disease (Fig. 1) . The association was even more evident when combining results of CT scans and K-ras analysis with corresponding serum levels of conventional tumor marker CA 19-9: K-ras mutations and elevated CA 19-9 were associated with CT findings of progressive disease in all but one case (12/13), whereas K-ras wild-type and normal CA 19-9 serum levels were associated with CT signs of disease remission or stable disease in most of the cases (14/21). Otherwise, of 70 plasma samples with detection of Kras wild type, 39 (56%) were associated with CT signs of progressive disease; but when additionally considering normal CA 19-9 levels, only 7 (10%) plasma samples with K-ras wild type were associated with corresponding disease progress in CT. Likewise, of 16 plasma samples with detection of K-ras mutation, 2 (13%) were associated with CT signs of disease remission; but when elevated CA 19-9 levels were considered in addition, then all plasma samples with detectable K-ras mutations were associated with corresponding disease progress in CT.
Taken together, our results suggest that detection of K-ras mutation in the plasma of patients with pancreatic cancer is a reliable marker of the course of disease, as CT findings of regressive or stable disease were associated with plasma K-ras wild type in most of the cases, and detectable K-ras mutations in the plasma were clearly associated with corresponding CT scans with signs of progressive disease. Although CT findings of disease progress were not necessarily associated with plasma K-ras mutations, combined determination of K-ras mutation and conventional tumor marker CA 19-9 led to a highly conclusive correlation with CT findings. In addition, K-ras analysis is suitable to add valuable information to serial monitoring of CA 19-9 levels, as we observed misleadingly elevated CA 19-9 levels in serum samples, whereas corresponding CT scans showed disease remission and plasma samples showed no K-ras mutation. Furthermore, some 5% to 10% of the population do not express Lewis antigens and do not have detectable CA 19-9 levels, and CA 19-9 is elevated in only approximately 65% of individuals with a resectable pancreatic cancer. 9 Thus, the combination of both tests, that is, the detection of K-ras alterations in the DNA of peripheral blood and the determination of CA 19-9 level, could be useful to assess cancer diagnosis in patients with normal or noncontributive CA 19-9 levels and also to provide additional supportive information.
In conclusion, we provide further evidence that detection of K-ras mutations in circulating tumor DNA may serve as a biomarker for disease progression and could therefore be useful for detection and prognostic evaluation of pancreatic carcinoma. Our approach of noninvasive, convenient, and extremely highly sensitive K-ras mutation analysis in plasma might provide diagnostic and prognostic information to physicians. However, the diagnostic finding of K-ras mutations has to be tempered by complementary imaging studies, laboratory tests (eg, CA 19-9) and the particular clinical context.
The authors declare no conflict of interest. FIGURE 1. Correlation of Kirsten rat sarcoma (K-ras) gene expression analysis in plasma (Wt, wild type; Mut, mutation) and serum levels of tumor marker carbohydrate antigen (CA) 19-9 (in IU/mL) with findings of contrast-enhanced CT of the abdomen during the clinical follow-up setting in patients with pancreatic cancer.
